Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Micro-Dose of bone protein make dental implants safer and stronger?

NCT ID NCT07696299

Disease control Sponsor: University of Baghdad Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study compares two doses of a bone-growth protein (rhBMP-2) against a placebo to see if a lower dose can improve dental implant stability while reducing side effects. Sixty adults needing a single implant in the lower jaw will be randomly assigned to receive a standard dose, a micro-dose, or a saline placebo during implant placement. Researchers will measure implant stability, bone loss, and complications like swelling and pain over 12 weeks. The goal is to find out if a smaller dose can work just as well with fewer problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
recombinant human bone morphogenetic protein-2 (rhBMP-2)
What this could lead to
If successful, this could lead to a safer, more affordable way to improve dental implant success by using a lower dose of a bone-growth protein.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The lower dose might not work as well as the standard dose, and there is a risk of side effects like swelling or pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 20 to 55 years requiring a single dental implant for a single tooth missing in the posterior mandible (strictly limited to one implant per patient to prevent clustering effects and intra-subject correlation). Patients must be systemically healthy or medically well-controlled, categorized as ASA I or ASA II according to the American Society of Anesthesiologists classification. Surgical sites must exhibit D2 or D3 bone quality with adequate residual alveolar bone volume (minimum 6 mm width and 10 mm height). Patients must maintain optimal oral hygiene, suitable for a prosthetically driven implant treatment workflow. Exclusion Criteria: * Patients presenting with uncontrolled systemic conditions (e.g., unmanaged diabetes mellitus, active osteoporosis). A history of radiotherapy or chemotherapy in the maxillofacial region. Current heavy smoking habits (\>10 cigarettes per day). Active and untreated periodontal disease. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dental implant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tooth Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dental implant Osseo-integrated implants Tooth loss / rehabilitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr. Mahdi Dental Clinic

    Baghdad, Baghdad Governorate, 10001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.